Patents Assigned to LIFE SCIENCE INSTITUTE, INC.
  • Publication number: 20230270790
    Abstract: Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease characterized by the progressive loss of motor neurons. Muse cells are endogenous reparative pluripotent-like stem cells distributed to various tissues. Once intravenously injected, such cells, upon sensing sphingosine-1-phosphate produced by damaged cells, settle selectively on damaged sites, and after homing, can exhibit multiphase effects including natural differentiation into tissue-protecting and tissue-reconstructing cells. In the present invention, with G93A-Tg mice serving as an ALS model, human Muse cells injected intravenously successfully homed into the lumbar cord, mainly at the pia mater and the lower white matter, and expressed glial-like forms and GFAP. Meanwhile, no such homing or differentiation was observed in the case of human mesenchymal stem cells (MSCs), and, rather, MSCs were found distributed to the lungs.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 31, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Koji ABE, Toru YAMASHITA, Mari DEZAWA, Yoshihiro KUSHIDA, Yumiko IWASE
  • Publication number: 20230203436
    Abstract: The high-potential pluripotent stem cells of the present invention not only have characteristics of conventional Muse cells, namely, are capable of differentiating into any embryonic tissue serving as all cells constituting the body, but also are capable of differentiating into any extraembryonic tissue cells such as placenta and/or germline cells, namely, have differentiation capacities close to totipotency. Thus, the high-potential pluripotent stem cells not only allow for conventional regenerative therapies of various diseases which cause any damage in constitution of the body, but also are capable of differentiating into any extraembryonic tissue cells such as placenta, and thus can allow any damaged sites in such any extraembryonic tissue to be re-constituted, resulting in improvement or restoring of the function of such any damaged sites, and can be applied to a new field of regenerative therapy, for example, can be used in reproductive therapies such as fertility therapy.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 29, 2023
    Applicants: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Mari DEZAWA, Yoshihiro KUSHIDA
  • Publication number: 20220395536
    Abstract: An object is to provide a cell product for treating and/or preventing vascular dementia. The present invention provides a cell product for treating or preventing vascular dementia, containing a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 15, 2022
    Applicants: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Kuniyasu NIIZUMA, Teiji TOMINAGA
  • Publication number: 20220387507
    Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.
    Type: Application
    Filed: October 30, 2020
    Publication date: December 8, 2022
    Applicants: Life Science Institute, Inc., National University Corporation Tokai National Higher Education and Research System, THE JIKEI UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Tokunori YAMAMOTO, Shinobu SHIMIZU, Akira FURUTA, Mari DEZAWA, Yasumasa KURODA
  • Publication number: 20220370510
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: July 29, 2022
    Publication date: November 24, 2022
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Publication number: 20220323509
    Abstract: Provided is a cell product for treating myocarditis, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.
    Type: Application
    Filed: September 4, 2020
    Publication date: October 13, 2022
    Applicants: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Mari DEZAWA, Yoshikatsu SAIKI, Hiroki TAKAYA
  • Patent number: 11419899
    Abstract: A cell product for prevention and/or treatment of vascular disorders such as aortic aneurysm, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell (Muse cell).
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 23, 2022
    Assignees: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE INC.
    Inventors: Yoshikatsu Saiki, Mari Dezawa, Katsuhiro Hosoyama
  • Publication number: 20220169979
    Abstract: This disclosure describes efficient methods for separating desired populations of cells, including Multilineage-Differentiating Stress-Enduring (MUSE) cells. Also described are the methods for isolating and enriching MUSE cells through a sorting, expanding, and re-sorting procedure. The enriched cells or cell populations can be used for treating cancer, repairing various tissues, and treating various degenerative or inherited diseases.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 2, 2022
    Applicants: Rutgers, The State University of New Jersey, Life Science Institute, Inc.
    Inventors: Wise Young, Dongming Sun, Iman Tadmori, Zikuan Leng, Mari Dezawa
  • Publication number: 20220156932
    Abstract: Provided are a skin disease analysis program, a skin disease analysis method, a skin disease analyzer, and a skin disease analysis system, which can analyze skin disease more accurately.
    Type: Application
    Filed: March 26, 2020
    Publication date: May 19, 2022
    Applicants: University of Tsukuba, SOINN Inc., Life Science Institute, Inc.
    Inventors: Yasuhiro FUJISAWA, Kodai IWASHITA, Mitsuyoshi ISHIDA
  • Publication number: 20220000936
    Abstract: A cell product may be used for treating a peripheral blood flow disorder, and the cell product may include an SSEA-3-positive pluripotent stem cells (Muse cells) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. The peripheral blood flow disorder is preferably a peripheral arterial disease, more preferably chronic arterial obstruction in a limb.
    Type: Application
    Filed: November 29, 2019
    Publication date: January 6, 2022
    Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Satoaki MATOBA, Mari DEZAWA
  • Publication number: 20210228638
    Abstract: A cell product for treatment of spinal cord injury, comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. Preferably, the spinal cord injury is complete or incomplete spinal cord injury.
    Type: Application
    Filed: May 9, 2019
    Publication date: July 29, 2021
    Applicant: LIFE SCIENCE INSTITUTE, INC.
    Inventors: Makoto KAWAMURA, Naoya MASUTOMI
  • Publication number: 20210233660
    Abstract: There are provided an estimation system, an estimation program and an estimation method through which voice spoken by a subject is estimated, a disease from which the subject is suffering is distinguished and estimated, aggravation of the disease is prevented, and patients are able to receive appropriate treatment based on accurate distinguishing of the disease.
    Type: Application
    Filed: July 11, 2019
    Publication date: July 29, 2021
    Applicants: Life Science Institute, Inc., PST Inc.
    Inventors: Yasuhiro OMIYA, Yorio KUMAMOTO
  • Publication number: 20210213068
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 15, 2021
    Applicants: LIFE SCIENCE INSTITUTE, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa, Teiji Tominga
  • Patent number: 10993966
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: May 4, 2021
    Assignees: LIFE SCIENCE INSTITUTE, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa, Teiji Tominaga
  • Publication number: 20200206272
    Abstract: A cell product for treatment of epidermolysis bullosa, comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. Preferably, the epidermolysis bullosa is epidermolysis bullosa simplex, junctional epidermolysis bullosa, or dystrophic epidermolysis bullosa.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 2, 2020
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Hiroshi SHIMIZU, Yasuyuki FUJITA, Naoya MASUTOMI
  • Publication number: 20200197446
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: June 20, 2018
    Publication date: June 25, 2020
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Patent number: 10641762
    Abstract: Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: May 5, 2020
    Assignees: UNIVERSITY OF TOYAMA, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Mari Dezawa, Satoshi Kuroda
  • Publication number: 20190290702
    Abstract: The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition both for ameliorating and treating perinatal brain damage including learning disability and motor disability, each of the cell preparation and the pharmaceutical composition containing SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue collected from a living body or cultured mesenchymal cells. The cell preparation according to the present invention relies on a mechanism that Muse cells are administered to a subject having the above-mentioned damage to cause the engraftment of the Muse cells in a damaged brain tissue, thereby ameliorating and treating the damage.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 26, 2019
    Applicants: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Yoshiaki Sato, Toshihiko Suzuki, Shinobu Shimizu, Masaaki Mizuno, Masahiro Hayakawa, Mari Dezawa
  • Publication number: 20190240262
    Abstract: The purpose of the present invention is to provide a novel medical use of pluripotent stem cells (Muse cells) in the regenerative medicine area. Provided are a cell preparation and a medicinal composition for ameliorating and treating chronic lung disease in newborns, said cell preparation and medicinal composition comprising SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue in a living body or cultured mesenchymal cells. The cell preparation according to the present invention is based on a mechanism whereby the aforesaid disease is ameliorated and treated by administering Muse cells to a subject suffering from the disease and engrafting the cells in lung tissues.
    Type: Application
    Filed: August 3, 2017
    Publication date: August 8, 2019
    Applicants: National University Corporation Nagoya University, Life Science Institute, Inc., TOHOKU UNIVERSITY
    Inventors: Yoshiaki SATO, Toshihiko SUZUKI, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA
  • Publication number: 20190201456
    Abstract: The purpose of the present invention is to provide a novel medical use of pluripotent stem cells (Muse cells) in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition which contain SSEA-3 positive pluripotent stem cells isolated from mesenchymal tissue of a living organism or cultured mesenchymal cells, and which are intended for alleviation and treatment of ischemia reperfusion-induced lung injury. The cell preparation according to the present invention is based on a mechanism in which Muse cells are administered to a subject having the abovementioned disease to engraft the cells into lung tissues, and the disease is alleviated and treated.
    Type: Application
    Filed: August 3, 2017
    Publication date: July 4, 2019
    Applicant: Life Science Institute, Inc.
    Inventors: Hiroshi YABUKI, Yoshinori OKADA, Mari DEZAWA